Brain Cancer Diagnostics Market: Market Size & Forecast 2026

Brain cancer diagnostics encompasses the equipment, reagents, and clinical workflows used to identify and grade primary and metastatic brain tumors, spanning conventional imaging, tissue and liquid biopsies, and emerging molecular tests. The market is currently worth about $2.55 billion in 2025 and is on track to reach roughly $3.5 billion by 2030, reflecting a compound annual growth rate near 7.47%. Demand is being supported by an aging global population, higher reported incidence of central nervous system malignancies, and growing investment in neuroimaging infrastructure across both developed and emerging healthcare systems.

• •Estimated global market size of approximately $2.55 billion in 2025 with a ~7.47% CAGR.
• •Forecast value of about $3.5 billion by the early 2030s.
• •Coverage spans imaging systems, biopsy procedures, molecular diagnostics, and consumables.

Rising global incidence of primary and secondary brain tumors, particularly among adults over 60, is expanding the addressable patient pool for diagnostic services. Adoption of high-resolution MRI, CT, and PET imaging, combined with reimbursement expansion in outpatient settings, is increasing test volumes per patient. At the same time, demand for molecular profiling and AI-assisted image analysis is pushing hospitals and reference labs to upgrade their diagnostic platforms.

• •Aging populations and improved cancer registry data are lifting reported brain tumor incidence.
• •Reimbursement and capital investment in 3T MRI, PET-CT, and intraoperative imaging are widening access.
• •AI-based image analysis, liquid biopsy, and next-generation sequencing are creating new high-value test categories.

By offering, the market is split between diagnostic instruments (predominantly MRI, CT, and PET systems) and consumables and services, with imaging continuing to account for the largest revenue share. By tumor type, primary brain tumors such as gliomas and meningiomas represent the bulk of procedures, while metastatic cases are a faster-growing segment as systemic cancer survival improves. Geographically, North America holds the leading share due to high imaging density and early adoption of molecular diagnostics, followed by Europe, while Asia-Pacific is the fastest-growing region as China and India expand oncology infrastructure.

• •Imaging dominates revenue, while molecular testing and liquid biopsy are the fastest-growing sub-segments.
• •Gliomas, meningiomas, and metastatic brain tumors are the principal tumor categories served.
• •North America leads today; Asia-Pacific is expanding fastest on the back of new diagnostic capacity.

What are the recent trends and outlook?

Through the rest of the decade, the market is expected to be shaped by the integration of AI into MRI and CT interpretation, broader use of liquid biopsy for treatment monitoring, and the rollout of personalized oncology programs that tie diagnostics directly to therapy selection. Hospitals are also moving toward multimodal platforms that combine imaging, pathology, and genomic data in a single diagnostic pathway for brain tumor patients. Combined, these trends support a continuation of mid-to-high single-digit annual growth and a market value approaching $3.5 billion by 2030.

• •AI-assisted image analysis and radiomics are moving from pilot projects into routine neuro-radiology workflows.
• •Liquid biopsy and cfDNA-based assays are being adopted for monitoring recurrence and treatment response.
• •Multimodal diagnostic pathways linking imaging, pathology, and genomics are becoming the standard of care at major cancer centers.